Compare CLNE & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLNE | NPCE |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.4M | 485.6M |
| IPO Year | 2006 | 2021 |
| Metric | CLNE | NPCE |
|---|---|---|
| Price | $2.13 | $14.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $3.49 | ★ $18.33 |
| AVG Volume (30 Days) | ★ 994.9K | 206.8K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $341,599,000.00 | $99,986,000.00 |
| Revenue This Year | $5.99 | $0.93 |
| Revenue Next Year | $17.00 | $25.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.13 |
| 52 Week Low | $1.30 | $7.56 |
| 52 Week High | $3.11 | $18.97 |
| Indicator | CLNE | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 35.82 | 47.31 |
| Support Level | $2.13 | $12.47 |
| Resistance Level | $2.30 | $16.96 |
| Average True Range (ATR) | 0.11 | 0.82 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 1.64 | 58.23 |
Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas and liquefied natural gas for the United States (U.S.) and Canadian transportation markets. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The firm operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. It also builds, operates, and maintains natural gas fueling stations for customers.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.